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The current pandemic of cholera is caused primarily by Vibrio cholerae 01 of the El Tor
biotype. Live attenuated classicalbiotype V. cholerae vaccinestrains prevent severeand moderate
cholera due to either biotype in challenged volunteers but may provide less protection against
mild cholera due to El Tor organisms. CVD 110, a new ctxA-deleted vaccinestrain derived from
an El Tor Ogawa parent, lacks zona occludens toxin (Zot), accessorycholera enterotoxin (Ace),
and hemolysin/enterotoxin. Ten healthy adult volunteers were given 108 cfu of CVD 110 with
buffer;7 developed diarrhea (mean stool volume, 861 mL). Vaccineorganisms wereshed in stool
by all vaccinees and were recovered from duodenal fluid in three-quarters of vaccinees. After
vaccination, the geometric mean peak reciprocal vibriocidal titer among vaccinees was 17,829.
CVD 110 is a powerful immunogen but insufficiently attenuated despite the absence of known
potential enterotoxins of V. cholerae. Another unrecognized toxin or colonization alone may be
responsible for diarrhea after ingestion of this strain.
The severe purging ofcholera characterized by the passage
of voluminous rice water stools ('-"'-1 L/h in adults) is due to
the effects ofcholera enterotoxin (CT). This toxin consists of
one enzymatically active A subunit (encoded by ctxA) and
five nontoxic but immunogenic B subunits (encoded by
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ctxB). Attenuated Vibriocholerae 0 1strains can be prepared
by precise deletion of genes that encode CT, the primary
virulence property, leaving intact the various other antigens
involved in stimulating a protective immune response.
Several such vaccine strains have been created from patho-
genic parent strains whose ability to cause cholera and to
stimulate protective immunity has been documented in vol-
unteer studies [1]. JBK 70 is a dctxA dctxB derivative of
virulent El Tor Inaba strain N 16961 in which the genes en-
coding both the A and B subunits ofCT were deleted (d) by
recombinant techniques. While notably attenuated com-
pared to its wild-type parent, JBK 70 nevertheless caused
mild diarrhea in 6 of 14 recipients of the vaccine, accompa-
nied by malaise, abdominal cramps, nausea, and headache.
A dctxA derivative of virulent classical Ogawa strain 395,
CVD 101,was fed to volunteers to determine whether geneti-
cally engineered vaccine strains derived from classical parent
strains might be better tolerated than El Tor derivatives. Un-
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like JBK (0, this strain expressed the immunogenic B sub-
unit of CT. At every dosage, CVD 101 colonized well and
elicited excellent vibriocidal and antitoxin responses, but
again, a proportion of the vaccinees had mild diarrhea, mal-
aise, and abdominal cramps [I].
In the search for a less reactogenic vaccine strain, the ctxA
gene was next deleted from wild-type classical Inaba V. chol-
erae 569B, also known to cause cholera in volunteers [2].
Notably, strain 569B was the only strain examined that did
not produce a cytotoxin that could be neutralized by anti-
serum prepared against Shiga toxin [3]. The resultant vac-
cine strain, CVD 103, was well tolerated in volunteers, and
the vibriocidal and antitoxin responses were prominent [2].
CVD 103 conferred significant protection against challenge
with V. cholerae of either classical or El Tor biotype and
either Inaba or Ogawa serotype [2]. A further derivative,
CVD 103-HgR, was constructed with a gene encoding resis-
tance to Hg++ ions inserted into the El Tor hemolysin gene
locus. The Hg++ resistance provides a helpful marker that
can be used to differentiate the vaccine strain from wild-type
V. cholerae classical Inaba strains. CVD 103-HgR was well
tolerated and protected volunteers against experimental
challenge with EI Tor Inaba N16961, EI Tor Ogawa E7946
(-- 60% protective efficacy against any diarrhea caused by
either strain), and classical Inaba 569B (100% protective effi-
cacy) [2, 4, 5].
Although CVD 103 and CVD 103-HgR provide 100%
protection against severe cholera ofboth classical and El Tor
biotypes, a minority of recipients of these classical biotype
vaccine strains develop mild diarrhea when challenged with
£1 Tor organisms (--60% protective). In the current pan-
demic, V. cholerae of the El Tor biotype are predominant,
and there are biotype-specific antigens that may contribute
to protective efficacy. Therefore, an El Tor strain that does
not cause diarrhea and provides protection against the most
epidemiologically important biotype of V. cholerae may be
desirable.
CVD 110 is a newly constructed ctxA-deleted, Hg++-resis-
tant strain derived from El Tor Ogawa E7946. Unlike the
reactogenic El Tor V. cholerae vaccine strain JBK 70, CVD
110 lacks the newly described zona occludens toxin (Zot)
and accessory CT (Ace), which may account for the diarrhea-
genicity of JBK 70 and CVD 101. Zot is a toxin present in
the supernatant of V. choleraecultures that affects intercellu-
lar tight junctions (zona occludens) of intestinal epithelial
cells, rendering them permeable to solute [6]. The activity of
Zot is measured in Ussing chambers in which the potential
difference, short-circuit current, and tissue conductance
across rabbit ileum are determined. Zot causes an increase in
tissue conductance, which is a sensitive measure of the func-
tional integrity of the intercellular tight junctions [6]. Zot
allows solute to permeate the paracellular space [6]. Ace is a
distinct toxin that causes an increase in potential difference
in Ussing chambers and secretion in rabbit ligated ileal loops
[7].The protein sequence of Ace is similar to eukaryotic ion
transporting ATPases. CT, Zot, and Ace comprise a genetic
virulence cassette that may contribute to the full pathogenic
potential of V. cholerae.
We sought to determine the clinical and immunologic re-
sponse to an El Tor strain lacking the four putative V. chol-
erae enterotoxins (El Tor hemolysin, CT, Zot, and Ace).
Materials and Methods
Volunteers. Healthy adults, 18 to 40 years old, from the Bal-
timore community were recruited to participate. Volunteers
were screened to confirm their good health by medical histories
and physical examinations, a battery of clinical hematology and
chemistry tests, electrocardiograms,and serologictests for syphi-
lis, hepatitis B surface antigen, and human immunodeficiency
virus. Before vaccination, stools were examined for bacterial
pathogens, ova, and parasites.
Vaccine. V. cholerae vaccine strain CVD 110 was grown,
lyophilized, and packaged at the Swiss Serum and Vaccine Insti-
tute, Berne, Switzerland. The formulation consisted of sachets
containing a single dose (3-5 X 108 viable organisms) oflyophi-
lized vaccine and 25 mg of aspartame. An accompanying sachet
contained an effervescent buffer powder consisting of 2.5 g of
sodium bicarbonate and 1.65 g of ascorbic acid. The vaccine
was stored at 4°C before use.
Vaccination. Volunteers were admitted to the Research Iso-
lation Ward of the Center for Vaccine Development located in
the University of Maryland Hospital. After a 48-h period of
acclimatization, 16 volunteers were randomized to receivea sin-
gle oral dose of r- 3-5 X 108 cfu of CVD 110 (n = 10) or an
identical appearing placebo (n = 6) consisting of buffer alone.
Placebo recipients were included to allow comparison of adverse
effectsand to monitor person-to-person transmission of vaccine
organisms among adults living in the isolation ward.
At the time of vaccination, a sachet of buffer was added to
100 mL of distilled water in a cup. A sachet containing a dose of
vaccine was then added to the buffer to make a vaccine cocktail.
The volunteers then ingested the cocktail. Volunteers had noth-
ing to eat or drink for 90 min before and after vaccination.
Volunteers were closely monitored in the isolation ward for
12 days after vaccination; vital signs were measured every 6 h.
All stools from each volunteer were collected in plastic con-
tainers, examined, and graded on a five-point scale [I], and the
volume was measured when the stool was loose. Volunteers
were interviewed daily by a physician and asked about symp-
toms. Diarrhea was defined as two or more loose stools within
48 h totaling ~200 mL in volume or a single loose stool ~300
mL in volume. Antibiotic therapy (500 mg tetracycline every 6
h for 5 days) was given before discharge.
Bacteriology. Every stool passed by volunteers after vaccina-
tion was cultured daily for the vaccine strain. Stool was plated
directly onto thiosulfate citrate bile salts sucrose (TCBS) agar
and into alkaline peptone water enrichment broth for overnight
incubation before plating onto TCBS agar. Up to three stools
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Table 1. Immunologic responses to V. cholerae vaccine strain
CVD 110.
NOTE. CT, cholera toxin; GM. geometric mean; Lf'Sc lipopolysaccha-
ride; 00. optical density; PBMC, peripheral blood mononuclear cells.
* Measured at 7 and 10 days after vaccination.
t On day 0, ;:;;3 cells producing antibody against any of the 3 antigens
were detected.
each day were cultured quantitatively to determine the number
of vaccine organismsper gram of stool.
At -- 20 and 44 h after vaccination, fasting volunteers swal-
lowed gelatin capsules containing string devices (Entero-Test;
HOC, Mountain View, CA) to collect samples of bile-stained
duodenal fluid. After 4 h, the strings were removed and the
color and pH of the distal 15 em were determined. Duodenal
fluid was squeezed from the end of the string and cultured as
described above.
Immunology. Serum samples were obtained before vaccina-
tion and on days 7, 10, 21, and 28 after vaccination. Titers of
vibriocidal antibodies were measured in serum [4] as well as
antibody responses to V. cholerae lipopolysaccharide (LPS)and
CT by ELISA[4]. A fourfold rise in titer was considered signifi-
cant.
Before and on days 7 and 10 after vaccination, heparinized
blood wascollectedforantibody secretingcell (ASC)determina-
tions. ASC of the IgG, IgM, and IgA classesagainst V. cholerae
oI-specific Inaba LPS and CT were measured by ELISPOT as
previously described [8]. Peripheral blood mononuclear cells
were separatedby ficoll-hypaque densitygradient centrifugation
(Organon Teknika, Durham, NC) and added to antigen-coated
or blank microtiter plates at a concentration of 0.25 X 106 cells/
well. Wellswererun in quadruplicate for each antigen-immuno-
globulin class. Data were expressed as the number of specific
ASCper 106 mononuclear cells. Four or more spotson the reac-
tion plate were considered significant.
No. of
responders
Assay (n = 10)
Ogawa vibriocidal antibody
(GM peak reciprocal titer)* 10
Inaba vibriocidal antibody
(GM peak reciprocal titer)* 10
Anti-CT (GM peak net 00)* 9
Antibody secreting cells
(GM peak no. of spots/
106 PBMC)*t
IgA anti-Ogawa LPS 9
IgM anti-Ogawa LPS 9
IgA anti-Inaba LPS 9














Clinical responses to vaccination. Eight of 10 vaccinees
had adverse reactions beginning 1-5 days after ingestion of
CVD 110. Seven of 10 vaccinees and none of 6 placebo
recipients developed diarrhea (thick liquid and opaque wa-
tery stools). The mean number ofstools was 6 (range, 2-13).
The three volunteers who did not have diarrhea did not have
preexisting ASC against V. cholerae Ogawa or Inaba LPS or
preexisting vibriocidal antibody. The mean diarrheal stool
volume was 861 mL (range, 377-1687). An additional vac-
cinee had fever (maximum temperature, 38.5°C), anorexia,
malaise, headache, and abdominal cramps on days 1 and 2
after vaccination, without diarrhea.
Recovery ofvaccine organisms in duodenalfiuid and stool.
Vaccine organisms were recovered in the stool cultures ofall
vaccinees for a mean of 7 days beginning in the first 72 h
after vaccination. The geometric mean peak excretion was
2.0 X 107 cfu/g, CVD 110 was recovered from duodenal
string fluids in 6 of 8 vaccinees who had at least 1 adequate
specimen. No vaccine organisms were recovered from the
stools or duodenal fluids of placebo recipients.
Serologic responses to vaccination. After vaccination with
a single oral dose of 108 cfu of CVD 110, all 10 vaccinees
developed fourfold or greater rises in serum Ogawa (homolo-
gous serotype) and Inaba (heterologous serotype) vibriocidal
antibodies with a geometric mean peak reciprocal titer after
vaccination of 17,829 and 3152, respectively (table 1). After
vaccination, 9 of 10 vaccinees who received CVD 110 devel-
oped significant rises in serum IgG antibody against CT (ta-
ble I).
ASC assays. ASC responses to Ogawa and Inaba LPS
and to CT were sought. All 10 vaccinees developed ASC to
Ogawa and Inaba LPS, or both (table I). Nine of 10 vacci-
nees developed IgA anti-Ogawa LPS ASC with a geometric
mean peak number of 161 cells/ I06 peripheral blood mono-
nuclear cells among responders (table I). Eight of 10 vacci-
nees developed IgA anti-CT B subunit with a geometric
mean peak number of 38 cells among responders. One pla-
cebo recipient had 6 ELISPOTS, indicating IgA anti-Inaba
LPS on day 10 after vaccination; no other ASC responses
occurred among placebo recipients.
Discussion
Three known potential enterotoxins (CT, Zot, Ace) are
encoded on a virulence cassette in the V. cholerae chromo-
some. El Tor strains also elaborate a hemolysin that has en-
terotoxic activity [9]. Deletion or inactivation of these four
virulence factors in strain E7946, however, yielded a strain
that still caused mild-to-moderate diarrhea in adult volun-
teers. Moreover, deletion of a putative colonization factor
(core-encoded pilin) encoded on this cassette [10] appar-
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ently did not reduce colonization to a clinically meaningful
extent. In previous studies in which volunteers received a
300- to 500-fold smaller dose (106 cfu) of V. cholerae £7946,
the fully virulent parent strain of CVD 110, the diarrhea
attack rate was 88%-100%, with a mean diarrheal stool vol-
ume of4.7 L ([11], unpublished data). Therefore, deletion of
CT, Zot, and Ace may have attenuated the parent wild-type
strain, but only partly.
In initial clinical studies of V. cholerae mutated in the ctx
gene, we proposed two possible explanations for the ability
of these strains to cause diarrhea and other symptoms [1].
The first hypothesis was that diarrhea after ingestion of CT-
deleted strains was due to an enterotoxin distinct from CT
that had not yet been recognized. The second hypothesis was
that diarrhea was due solely to colonization of the small
bowel by attenuated V.cholerae. It is not clear which explana-
tion accounts for the diarrheagenicity of CVD 110.
The assumption that all potential enterotoxins had been
removed from V. cholerae CVD 110 was based on Ussing
chamber studies showing that culture supernatants of CVD
110 caused no change in short circuit current (lsc) in rabbit
ileal tissue. Genes for three toxins, CT, Zot and Ace, which
had been shown to increase lsc, had been removed from
CVD 110. In addition, the gene for the hemolysin/cytotoxin
of V. cholerae, which has been shown to cause fluid accumu-
lation in ligated rabbit ileal loops [12], was also mutated in
CVD 110. The results of the volunteer study suggest that
there is yet another toxin(s) produced by V. cholerae that can
cause diarrhea and other symptoms. It was suggested previ-
ously that a Shiga-like toxin may be responsible for the reac-
togenicity of CT-deleted strains of V. cholerae, but this has
never been proven [3].
The Ussing chamber is a classic technique for detecting
and characterizing enterotoxins, and there is significant liter-
ature on the activity of CT and Escherichia coli heat-stabile
enterotoxin in increasing Isc in Ussing chambers. If there is
another enterotoxin produced by CVD 110, there are a num-
ber of potential reasons why supernatants from CVD 110
cultures did not alter Ussing chamber activity: The toxin
may not be active on rabbit tissue but may be active on hu-
man tissue; the culture conditions used to grow CVD 110 for
Ussing chamber assays may not favor expression of the
toxin; the toxin may not be present in the supernatant as are
CT, Zot, and Ace but instead may be cell-associated and
unlikely to be detected in culture supernatants; or the toxin
may be electrogenically silent (such as the Shiga toxin pro-
duced by Shigella dysenteriae) [13].
An alternative explanation for the residual diarrheagenic
potential of CVD 110 is that avid adherence to enterocytes
ofthe proximal small bowel may somehow result in secretion
leading to diarrhea. This hypothesis is supported by experi-
ments of Smith and Linggood [14], who demonstrated that
in piglets, E. colistrains that express both a colonization fac-
tor (K88) and enterotoxin cause diarrhea. Moreover, E. coli
strains that had lost the enterotoxin but still expressed K88
pili were able to cause diarrhea in about one-third ofinfected
animals. Using a strain of enterotoxigenic E. coli originally
isolated from a patient, Wanke and Guerrant [IS] showed
that a derivative that had lost the enterotoxin but still pos-
sessed colonization factor antigen/Il could cause diarrhea in
the rabbit reversible ileal tie model. These authors suggest
that normal metabolic or enzymatic products of the coloniz-
ing bacteria might act directly in the gut as secretagogues or
as agents capable of altering gut absorption or gut motility
acting through the enteric nervous system. A subsequent
study by these investigators showed that colonization of the
ileum with this nontoxigenic E. colistrain caused reversal of
the normal net ileal absorption to net secretion of water,
sodium, and chloride as well as a significant decrease in mu-
cosal sucrase activity [16]. We have previously shown that
the same strain used by these investigators also caused mild
diarrhea in 2 of 19 volunteers who ingested 109 or 1010 cfu of
organism [17]. However, it is difficult, if not impossible, to
determine with certainty that these putatively non toxigenic
strains do not produce a toxin that is undetectable by the
conventional assays and growth conditions used.
While it is difficult to accurately assess intestinal coloniza-
tion in volunteer studies, the extremely high vibriocidal anti-
body levels and long duration of stool shedding seen with
CVD 110 indicate that this strain colonizes the human intes-
tine very well. "Colonization" may include two types of in-
teraction of vaccine organisms with mucosal cells: antigenic
uptake by M cells overlying the gut-associated lymphoid tis-
sue (which leads to an immune response) and adherence to
enterocytes (which may lead to diarrhea). The vigorous im-
mune response after ingestion of CVD 110 indicates that
CVD 110 attaches to and is taken up by M cells; it is not
clear whether this process or adherence to enterocytes re-
sulted in diarrhea. In our small study, volunteers with nega-
tive duodenal fluid cultures nevertheless had large volumes
ofdiarrhea and excellent immune responses, suggesting that
both types ofcolonization occurred. CVD I03-HgR does not
colonize the human intestine as well as does CVD 110 but is
highly immunogenic; perhaps the lack of reactogenicity of
CVD 103-HgR is in part due to decreased adherence to en-
terocytes. Future studies in search of additional V. cholerae
toxins are ongoing, and the search for a nonreactogenic EI
Tor vaccine strain will continue.
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